Sale

Osteoarthritis Therapeutics Market

Osteoarthritis Therapeutics Market Share, Growth, Forecast: By Type: Hip Osteoarthritis, Spinal Osteoarthritis, Knee Osteoarthritis, Hand Osteoarthritis, Others; By Drug Class: Analgesics, Corticosteroids, Others; By Doses Form; By Route of Administration, By End User; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032

Osteoarthritis Therapeutics Market Outlook

The osteoarthritis therapeutics market size was valued at USD 9.13 billion in 2023, driven by the increasing geriatric population across the globe. The market size is anticipated to grow at a CAGR of 8.7% during the forecast period of 2024-2032 to achieve a value of USD 19.35 billion by 2032.

 

Osteoarthritis Therapeutics: Introduction

Millions of people are suffering from osteoarthritis, which is the most prevalent kind of arthritis. It happens due to damage of the protective cartilage that cushions the ends of the bones. Even though osteoarthritis can harm any joint, it most frequently affects the hands, knees, hips, and spine. While the damage to joints cannot be undone, osteoarthritis symptoms can typically be controlled. The progression of the disease may be slowed down, and pain and joint function may be improved by staying active, maintaining a healthy weight, and obtaining specific therapies.

 

Osteoarthritis Therapeutics Market Analysis

There have been multiple research studies going on to develop new effective drugs for the treatment of osteoarthritis. The researchers launched a combined safety and preliminary efficacy clinical trial (Phases I and IIa) of R805/CX-011 for the treatment of OA in patients. This clinical trial was followed by their previously successful animal-based trial which was performed on a rat and was concluded to be effective. For this trial, around 70 patients test knee injections of R805/CX-011 will be tested.

 

This may provide a less expensive alternative, also a less invasive option, which would be easy to administer several times a year, with a high potential of delaying or even reducing the need for surgical procedures, further propelling the market growth. More people would want to get treated with less invasive procedures. Researchers are also trying to test the efficacy of R805/CX-011 to promote tissue regeneration in a range of other conditions, such as pulmonary fibrosis and bone loss. This would further aid the osteoarthritis therapeutics market growth.

 

The key players in the market are focused on launching new and effective products to curb osteoarthritis discomfort in patients, which is propelling the market growth. For instance, the FDA approved the MISHA Knee System, that is an implantable shock absorber effective in partially reducing load on knee joint. This load reduction is expected to result in reduced pain and preserving functionality of the knee. This device would be implanted subcutaneously during an outpatient-compatible procedure. Such approvals are directly contributing to the market growth.

 

Osteoarthritis Therapeutics Market Segmentations

Market Breakup by Type

  • Hip Osteoarthritis
  • Spinal Osteoarthritis
  • Knee Osteoarthritis
  • Hand Osteoarthritis
  • Others

 

Market Breakup by Drug Class

  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  • Analgesics
  • Corticosteroids
  • Hyaluronic Acid Injections
  • Disease-modifying Osteoarthritis Drugs
  • Others

 

Market Breakup by Doses Form

  • Tablets and Capsules
  • Injections
  • Creams and Gels
  • Others

 

Market Breakup by Route of Administration

  • Oral
  • Parenteral
  • Topical

 

Market Breakup by End User

  • Hospitals
  • Specialty Clinics
  • Homecare Settings
  • Others

 

Market Breakup by Distribution Channel

  • Hospitals Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

 

Market Breakup by Region-7MM

  • United States
  • EU-4 and the United Kingdom
  • Japan

 

Osteoarthritis Therapeutics Market Overview

The rising geriatric population is a major factor influencing the market growth due to the rising bone related issues in geriatric population. It is very common in older to people to develop such joint issues for example joint pain, discomfort while walking or exercising among other factors. The chances of developing osteoarthritis in women are more in comparison to men after the age of 50. According to WHO, 1 in every 6 people in the world will be aged 60 years of age or over by 2030. By 2050, the world’s population of people aged 60 years and older will double (2.1 billion). The number of persons aged 80 years or older is expected to triple between 2020 and 2050 to reach 426 million.

 

With this data, a rise in osteoarthritis case is expected in coming years which is directly contribute to the market growth. The increasing advancements, research and development for drug development are also driving the osteoarthritis therapeutics market growth.

 

The rising initiatives of investments from both private & government organizations to empower the development of healthcare sector and research facilities are a major factor driving the market growth. There has been a significant rise in demand for cell-based research activities, which is likely to further aid the osteoarthritis therapeutics market share.

 

Due to rising number of research, more drugs are being developed, more clinical trials for the approval are needed to test the potential and efficacy of such drugs. Therefore, increasing number of drug approvals are anticipated to fuel the growth of the market.

 

Osteoarthritis Therapeutics Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

 

  • Pfizer Inc.
  • Abbive Inc.
  • Novartis AG
  • Amgen Inc.
  • Boehringer Ingelheim International GmbH.
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • AstraZeneca PL
  • Zimmer Biomet 
  • Stryker Corporation

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Type
  • Drug Class
  • Doses Form
  • Route of Administration
  • End User
  • Distribution Channel
  • Region-7MM
Breakup by Type
  • Hip Osteoarthritis 
  • Spinal Osteoarthritis 
  • Knee Osteoarthritis 
  • Hand Osteoarthritis 
  • Others 
Breakup by Drug Class
  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs) 
  • Analgesics 
  • Corticosteroids 
  • Hyaluronic Acid Injections 
  • Disease-modifying Osteoarthritis Drugs 
  • Others 
Breakup by Doses Form
  • Tablets & Capsules 
  • Injections 
  • Creams and Gels 
  • Others
Breakup by Route of Administration
  • Oral 
  • Parenteral 
  • Topical 
Breakup by End User
  • Hospitals 
  • Specialty Clinics 
  • Homecare Settings 
  • Others 
Breakup by Distribution Channel
  • Hospitals Pharmacy 
  • Retail Pharmacy 
  • Online Pharmacy 
  • Others 
Breakup by Region-7MM
  • United States
  • EU-4 and the United Kingdom
  • Japan
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Pfizer Inc.
  • Abbive Inc.
  • Novartis AG
  • Amgen Inc.
  • Boehringer Ingelheim International GmbH.
  • F. Hoffmann-La Roche Ltd. 
  • Merck & Co Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • AstraZeneca PL
  • Zimmer Biomet
  • Stryker Corporation

 

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Osteoarthritis Overview

    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Osteoarthritis Epidemiology Analysis-7MM
    5.1    Epidemiology Overview (2016-2031)
    5.2    United States Osteoarthritis Epidemiology (2016-2031)
    5.3    EU-4 and United Kingdom Osteoarthritis Epidemiology (2016-2031)
    5.4    Japan Osteoarthritis Epidemiology (2016-2031)
6     Osteoarthritis Therapeutics Market Overview 
    6.1     Osteoarthritis Therapeutics Market Historical Value (2017-2023) 
    6.2     Osteoarthritis Therapeutics Market Forecast Value (2024-2032)
7     Osteoarthritis Therapeutics Market Landscape
    7.1    Osteoarthritis Therapeutics: Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Osteoarthritis Therapeutics: Product Landscape
        7.2.1    Analysis by Therapy Type
        7.2.2    Analysis by Drug Class
        7.2.3    Analysis by Route of Administration
8    Osteoarthritis Therapeutics Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
10     Osteoarthritis Therapeutics Market Dynamics
    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model
    10.4    Key Demand Indicators 
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends  
    10.7    Value Chain Analysis
11     Osteoarthritis Therapeutics Market Segmentation
    11.1     Osteoarthritis Therapeutics Market by Type 
        11.1.1    Market Overview 
        11.1.2    Hip Osteoarthritis 
        11.1.3    Spinal Osteoarthritis 
        11.1.4    Knee Osteoarthritis 
        11.1.5    Hand Osteoarthritis 
        11.1.6    Others 
    11.2     Osteoarthritis Therapeutics Market by Drug Class 
        11.2.1    Market Overview 
        11.2.2    Nonsteroidal Anti-inflammatory Drugs (NSAIDs) 
        11.2.3    Analgesics 
        11.2.4    Corticosteroids 
        11.2.5    Hyaluronic Acid Injections 
        11.2.6    Disease-modifying Osteoarthritis Drugs 
        11.2.7    Others 
    11.3    Osteoarthritis Therapeutics Market by Doses Form 
        11.3.1    Market Overview 
        11.3.2    Tablets & Capsules 
        11.3.3    Injections 
        11.3.4    Creams and Gels 
        11.3.5    Others 
    11.4    Osteoarthritis Therapeutics Market by Route of Administration 
        11.4.1    Market Overview 
        11.4.2    Oral 
        11.4.3    Parenteral 
        11.4.4    Topical 
    11.5    Osteoarthritis Therapeutics Market by End User 
        11.5.1    Market Overview 
        11.5.2    Hospitals 
        11.5.3    Specialty Clinics 
        11.5.4    Homecare Settings 
        11.5.5    Others 
    11.6    Osteoarthritis Therapeutics Market by Distribution Channel 
        11.6.1    Market Overview 
        11.6.2    Hospitals Pharmacy 
        11.6.3    Retail Pharmacy 
        11.6.4    Online Pharmacy 
        11.6.5    Others 
    11.7     Osteoarthritis Therapeutics Market by Region-7MM
        11.7.1    Market Overview
        11.7.2    United States
        11.7.3    EU-4 and the United Kingdom
        11.7.4    Japan
12    United States Osteoarthritis Therapeutics Market
    12.1    U.S. Osteoarthritis Therapeutics Market Historical Size (2017-2023)  
    12.2    U.S. Osteoarthritis Therapeutics Market Forecast Size (2024-2032)  
    12.3    Market Size by Drug Class
13    EU-5 and the United Kingdom Osteoarthritis Therapeutics Market
    13.1    EU-5 and the United Kingdom Osteoarthritis Therapeutics Market Historical Size (2017-2023)  
    13.2    EU-5 and the United Kingdom Osteoarthritis Therapeutics Market Forecast Size (2024-2032)  
    13.3    Market Size by Drug Class
14    Japan Osteoarthritis Therapeutics Market
    14.1    Japan Osteoarthritis Therapeutics Market Historical Size (2017-2023)  
    14.2    Japan Osteoarthritis Therapeutics Market Forecast Size (2024-2032)  
    14.3    Market Size by Drug Class
15    Regulatory Framework
    15.1    Regulatory Overview
        15.1.1    US FDA
        15.1.2    EU EMA
        15.1.3    JAPAN PMDA
16    Patent Analysis
    16.1    Analysis by Type of Patent
    16.2    Analysis by Publication year
    16.3    Analysis by Issuing Authority
    16.4    Analysis by Patent Age
    16.5    Analysis by CPC Analysis
    16.6    Analysis by Patent Valuation 
    16.7    Analysis by Key Players
17    Grants Analysis
    17.1    Analysis by year
    17.2    Analysis by Amount Awarded
    17.3    Analysis by Issuing Authority
    17.4    Analysis by Grant Application
    17.5    Analysis by Funding Institute
    17.6    Analysis by NIH Departments
    17.7    Analysis by Recipient Organization 
18    Clinical Trials Analysis
    18.1     Analysis by Trial Registration Year
    18.2    Analysis by Trial Status
    18.3    Analysis by Trial Phase
    18.4    Analysis by Therapeutic Area
    18.5    Analysis by Geography
19    Funding and Investment Analysis
    19.1    Analysis by Funding Instances
    19.2    Analysis by Type of Funding
    19.3    Analysis by Funding Amount
    19.4    Analysis by Leading Players
    19.5    Analysis by Leading Investors
    19.6    Analysis by Geography
20    Partnership and Collaborations Analysis
    20.1    Analysis by Partnership Instances
    20.2    Analysis by Type of Partnership
    20.3    Analysis by Leading Players
    20.4    Analysis by Geography
21    Supplier Landscape
    21.1    Pfizer Inc.
        21.1.1    Financial Analysis
        21.1.2    Product Portfolio
        21.1.3    Demographic Reach and Achievements
        21.1.4    Mergers and Acquisitions
        21.1.5    Certifications
    21.2    Abbive Inc.
        21.2.1    Financial Analysis
        21.2.2    Product Portfolio
        21.2.3    Demographic Reach and Achievements
        21.2.4    Mergers and Acquisitions
        21.2.5    Certifications
    21.3    Novartis AG
        21.3.1    Financial Analysis
        21.3.2    Product Portfolio
        21.3.3    Demographic Reach and Achievements
        21.3.4    Mergers and Acquisitions
        21.3.5    Certifications
    21.4    Amgen Inc.
        21.4.1    Financial Analysis
        21.4.2    Product Portfolio
        21.4.3    Demographic Reach and Achievements
        21.4.4    Mergers and Acquisitions
        21.4.5    Certifications
    21.5    Boehringer Ingelheim International GmbH.
        21.5.1    Financial Analysis
        21.5.2    Product Portfolio
        21.5.3    Demographic Reach and Achievements
        21.5.4    Mergers and Acquisitions
        21.5.5    Certifications
    21.6    F. Hoffmann-La Roche Ltd. 
        21.6.1    Financial Analysis
        21.6.2    Product Portfolio
        21.6.3    Demographic Reach and Achievements
        21.6.4    Mergers and Acquisitions
        21.6.5    Certifications
    21.7    Merck & Co Inc.  
        21.7.1    Financial Analysis
        21.7.2    Product Portfolio
        21.7.3    Demographic Reach and Achievements
        21.7.4    Mergers and Acquisitions
        21.7.5    Certifications
    21.8    Teva Pharmaceutical Industries Ltd. 
        21.8.1    Financial Analysis
        21.8.2    Product Portfolio
        21.8.3    Demographic Reach and Achievements
        21.8.4    Mergers and Acquisitions
        21.8.5    Certifications
    21.9    Sun Pharmaceutical Industries Ltd. 
        21.9.1    Financial Analysis
        21.9.2    Product Portfolio
        21.9.3    Demographic Reach and Achievements
        21.9.4    Mergers and Acquisitions
        21.9.5    Certifications
    21.10    AstraZeneca PL 
        21.10.1    Financial Analysis
        21.10.2    Product Portfolio
        21.10.3    Demographic Reach and Achievements
        21.10.4    Mergers and Acquisitions
        21.10.5    Certifications
    21.11    Zimmer Biomet  
        21.11.1    Financial Analysis
        21.11.2    Product Portfolio
        21.11.3    Demographic Reach and Achievements
        21.11.4    Mergers and Acquisitions
        21.11.5    Certifications
    21.12    Stryker Corporation  
        21.12.1    Financial Analysis
        21.12.2    Product Portfolio
        21.12.3    Demographic Reach and Achievements
        21.12.4    Mergers and Acquisitions
        21.12.5    Certifications
22    Osteoarthritis Therapeutics - Distribution Model (Additional Insight)
    22.1    Overview 
    22.2    Potential Distributors 
    22.3    Key Parameters for Distribution Partner Assessment 
23    Key Opinion Leaders (KOL) Insights (Additional Insight)
24    Company Competitiveness Analysis (Additional Insight)

    24.1    Very Small Companies
    24.2    Small Companies
    24.3    Mid-Sized Companies
    24.4    Large Companies
    24.5    Very Large Companies
25    Payment Methods (Additional Insight)
    25.1    Government Funded
    25.2    Private Insurance
    25.3    Out-of-Pocket


*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The market attained a value of about USD 9.13 billion in 2023, driven by the increasing geriatric population.

The market is anticipated to grow at a CAGR of 8.7% during the forecast period of 2024-2032, and likely to reach a market value of USD 19.35 billion by 2032.

The rising geriatric population and increasing investments from governments and key players in research and development activities are major factors driving the market growth.

The increasing focus of key players to develop new drugs and other helpful solution to overcome or relieve osteoarthritis in elderly patients is a major trend influencing the market growth.

The major regions of the market include the United States, Japan, EU-4 and the United Kingdom.

There are hip osteoarthritis, spinal osteoarthritis, knee osteoarthritis, and hand osteoarthritis, among others.

Nonsteroidal Anti-inflammatory Drugs (NSAIDs), analgesics, corticosteroids, hyaluronic acid injections, disease-modifying osteoarthritis drugs, among others are all used to treat Osteoarthritis.

Various forms of dosage are tablets and capsules, injections, creams and gels, among others.

Different routes of administration include oral, parenteral, and topical.

Different end users in the market include hospitals, specialty clinics, and homecare settings, among others.

Different distribution channels in the market include hospitals pharmacy, retail pharmacy, and online pharmacy, among other pharmacies.

Key players involved in the market are Pfizer Inc., Abbive Inc., Novartis AG, Amgen Inc. Boehringer Ingelheim International GmbH., F. Hoffmann-La Roche Ltd., Merck & Co Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., AstraZeneca PL, Zimmer Biomet, and Stryker Corporation.

Key players involved in the market are Pfizer Inc., Abbive Inc., Novartis AG, Amgen Inc. Boehringer Ingelheim International GmbH., F. Hoffmann-La Roche Ltd., Merck & Co Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., AstraZeneca PL, Zimmer Biomet, and Stryker Corporation.

Purchase Full Report

Mini Report

$ 3299     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 6599     $5999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8799     $7999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 9899     $8999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER